选择性雄激素受体调节剂(SARMs)能否进入临床?
本文综述选择性雄激素受体调节剂(SARMs)的化学基础、临床前景及监管审批障碍。多种SARMs在临床试验中可增加瘦体重,但少有持续改善力量或活动能力的功能性结局;肝毒性和心血管风险等安全性问题尚未完全解决。部分SARMs正针对衰老和肌少症进行评估,未来可能进入特定人群的临床实践。
要点
- SARMs组织选择性好且可口服,拟用于肌萎缩、骨质疏松、性腺功能减退和衰弱。
- 临床试验中多种SARMs增加瘦体重,但功能性结局改善不一致。
- 肝毒性和心血管风险等安全性问题未完全解决,广泛获批需长期安全性和疗效证据。
核心结论
- SARMs可能在衰弱、老年或瘦体重过度丢失的特定男女亚群中进入临床实践。
- 广泛获批取决于未来试验同时证明疗效和长期安全性。
研究设计与样本
- 综述,介绍SARMs的化学基础、临床前景及限制监管审批的主要挑战。
主要发现
- 多种SARMs在临床试验中显示增加瘦体重的疗效。
- 少有SARMs在力量或活动能力等功能性结局上显示一致改善。
- 肝毒性和心血管风险等安全性问题仍未完全解决。
- 部分SARMs正针对衰老和肌少症相关适应症积极评估。
临床怎么用
- 关注SARMs在衰弱、老年或瘦体重过度丢失人群中的潜在应用。
- 临床使用前需权衡肝毒性和心血管风险,等待长期安全性数据。
局限性
- 功能性结局改善不一致,疗效证据有限。
- 肝毒性和心血管风险等安全性问题尚未完全解决。
- 广泛审批需未来试验验证疗效和长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Selective androgen receptor modulators (SARMs) are a novel class of compounds engineered to confer the anabolic benefits of testosterone such as increased muscle and bone mass while minimizing undesirable androgenic effects. Their tissue-selective activity and oral availability have sparked significant interest in their potential applications for conditions like muscle wasting, osteoporosis, hypogonadism, and frailty. We outline the chemical underpinnings of SARMs, their clinical promise, and the major challenges that have limited their regulatory approval to date. Although multiple SARMs have shown efficacy in increasing lean body mass in clinical trials, few have demonstrated consistent improvements in functional outcomes such as strength or mobility. Safety concerns, particularly regarding hepatotoxicity and cardiovascular risk, remain incompletely resolved. Nevertheless, a subset of SARMs is being actively evaluated for indications directly related to aging and sarcopenia. We conclude that SARMs are likely to enter clinical practice in select niches of men and women, especially among the frail, the elderly, or individuals with excessive loss of lean body mass. However, widespread approval will depend on future trials demonstrating both efficacy and long-term safety.
引用
- Dias JP, Dobs AS. Will Selective Androgen Receptor Modulators Ever Reach The Clinic? J Clin Endocrinol Metab. 2026. PMID: 41670367. doi:10.1210/clinem/dgaf700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。